We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





Virus-Fighting Enzymes in Bacteria Could Lead to Development of Highly Effective Antiviral Drugs Against COVID-19

By HospiMedica International staff writers
Posted on 23 Sep 2020
Print article
Image: The viperins in bacteria have evolved to fight a variety of viruses (Photo courtesy of Weizmann Institute of Science)
Image: The viperins in bacteria have evolved to fight a variety of viruses (Photo courtesy of Weizmann Institute of Science)
Virus-fighting viperins, part of the human immune system, which were previously known to exist only in mammals, have now been found in bacteria that could lead to the development of highly effective antiviral drugs for the treatment of COVID-19.

A group of scientists at the Molecular Genetics Department at the Weizmann Institute of Science (Rehovot, Israel) has uncovered a gold mine of antiviral substances made by virus-fighting enzymes known as viperins. The molecules produced by the bacterial viperins are currently undergoing testing against human viruses such as the influenza virus and COVID-19.

Earlier studies conducted by the group as well as other scientists have revealed that bacteria have highly sophisticated immune systems, despite their microscopic size. In particular, they are equipped to fight off phages - viruses that infect bacteria. These differ from the kind that infect humans in their choice of targets, but they all consist of genetic material - DNA or RNA - that hijacks parts of the host’s replication machinery to make copies of themselves and spread.

The group of scientists have now found that some of these bacterial immune responses suggest evolutionary links to our own immune systems, and the present study in their lab shows the strongest evidence yet: They discovered that viperin antiviral enzymes - whose function in the human immune system was understood only two years ago - play a role in the immune system of bacteria.

In humans, viperin belongs to the innate immune system, the oldest part of the immune system in terms of evolution. It is produced when a signaling substance called interferon alerts the immune system to the presence of pathogenic viruses. The viperin then releases a special molecule that is able to act against a broad range of viruses with one simple rule: The molecule “mimics” nucleotides, bits of genetic material needed to replicate their genomes. But the viperin molecule is fake: It is missing a vital piece that enables the next nucleotide in the growing strand to attach. Once the faux-nucleotide is inserted into the replicating viral genome, replication comes to a halt and the virus dies.

This simplicity and broad action against many different viruses suggested viperins had been around for some time, but could they go back as far as our common ancestors with bacteria? The group used techniques that had been developed in their lab to detect bacterial sequences encoding possible viperins. They then showed that these viperins did, indeed, protect bacteria against phage infection. Based on the genetic sequences, the team was able to trace the evolutionary history of viperins. If the bacterial viperins prove effective against human viruses, then it may pave the way for the discovery of further molecules generated by bacterial immune systems that could be adopted as antiviral drugs for human diseases. Further studies are underway to determine which of the bacterial viperins could be best adapted to fighting human viruses, including, of course, COVID-19.

“As we did decades ago with antibiotics - antibacterial substances that were first discovered in fungi and bacteria - we might learn how to identify and adopt the antiviral strategies of organisms that have been fighting infection for hundreds of millions of years,” said Prof. Rotem Sorek from the Institute’s Molecular Genetics Department.

Related Links:
Weizmann Institute of Science

Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Gold Member
12-Channel ECG
CM1200B
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Silver Member
ECG Management System
NEMS-Q

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.